Document is current
Any future updates will be listed below
-
Authors
Lindman, Brian R.
Perry, Andrew S. https://orcid.org/0000-0003-3342-6158
Lance, Michelle L.
Amancherla, Kaushik
Kim, Namju
Sheng, Quanhu https://orcid.org/0000-0001-8951-9295
Lin, Phillip
Pfeiffer, Ryan D.
Farber-Eger, Eric https://orcid.org/0000-0003-0281-3796
Fearon, William F.
Kapadia, Samir
Kumbhani, Dharam J.
Gillam, Linda
Mallugari, Ravinder R. https://orcid.org/0009-0002-0892-7102
Gupta, Deepak K.
Miller, Francis J.
Vatterott, Anna
Jackson, Natalie
Su, Yan Ru
Tomasek, Kelsey https://orcid.org/0009-0007-6576-8933
Absi, Tarek
Freedman, Jane E.
Nayor, Matthew
Das, Saumya https://orcid.org/0000-0002-4521-4606
Wells, Quinn S.
Dweck, Marc R.
Gerszten, Robert E. https://orcid.org/0000-0002-6767-7687
Gamazon, Eric R. https://orcid.org/0000-0003-4204-8734
Tucker, Nathan R.
Shah, Ravi https://orcid.org/0000-0002-4471-7156
Elmariah, Sammy https://orcid.org/0000-0002-8013-8733
- License Information
-
More Information
Article History
Received: 19 February 2025
Accepted: 14 July 2025
First Online: 26 July 2025
Competing interests
: Dr. Lindman is supported by R01HL164526 and R01AG073633 from the NIH, has received investigator-initiated research grant funding and consulted for Edwards Lifesciences, and consulted for Astra Zeneca, Medtronic, Kardigan, and Anteris. Dr. Perry has patents pending for proteomic signatures of fitness, lung, and liver disease. Dr. Amancherla is supported by an American Heart Association (AHA) Career Development Award (#929347), the NIH (K23HL166960), the Red Gates Foundation, and an International Society for Heart and Lung Transplantation Enduring Hearts Transplant Longevity Award. Dr. Amancherla has an institutional disclosure filed for spatial RNA biomarkers of transplant rejection and allograft health. Dr. Gerszten is supported by a Leducq foundation grant (21CVD01). Dr. Nayor supported by R01HL156975 and R01HL131029 from the NIH. Dr. Gillam is an advisor Medtronic, Philips, and Egnite and oversees core lab contracts with Edwards Lifesciences, Medtronic, and Abbott (no direct compensation). Dr Dweck is supported by the British Heart Foundation (FS/SCRF/21/32010) and is the recipient of the Sir Jules Thorn Award for Biomedical Research 2015 (15/JTA). Dr. Das is a founder of Thryv Therapeutics and Switch Therapeutics with equity in both, and has research grants from Bristol Myers Squibb, National Institutes of Health (R35HL 105807). Dr. Gupta is supported by R01HL153607, R01HL154153-03, R01HL148661, R01AG034962, and R01HL145293 from the NIH and is patent holder (#11,079,394) for detection of angiopoietin-2 and thrombospondin-2 for the diagnosis of acute heart failure. Dr. Miller is supported by the Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. Dr. Tucker is supported by the NIH R01-HL170051. Dr. Gamazon is a consultant for Thryv Therapeutics, and is a co-inventor on pending patents or disclosures on cardiovascular diseases and phenotypes, and metabolic health, use of RNAs as therapeutics and diagnostic biomarkers in disease, and methods in metabolomics. Dr. Shah is supported by grants from the National Institutes of Health. Dr. Shah has equity ownership in and is a consultant for Thryv Therapeutics. Dr. Shah is a co-inventor on pending patents or disclosures on molecular biomarkers of fitness, lung disease, cardiovascular diseases and phenotypes, and metabolic health, use of RNAs (including spatial) as therapeutics and diagnostic biomarkers in disease, and methods in metabolomics. Dr. Elmariah is supported by institutional research grants from the NIH (5R01HL151838), the Patient-Centered Outcomes Research Institute, Edwards Lifesciences, Medtronic, and Abbott. Dr. Elmariah is a consultant for Edwards Lifesciences and holds equity and is co-founder of Prospect Health. The remaining authors have no relevant disclosures.
